Therapeutic Effectiveness and Safety Outcomes of Generic and Original Piperacillin/Tazobactam for infection in Tertiary Referral Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20250216005

Enrollment

400

Registered

2025-02-16

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hospitalized infection Patients received Piperacillin/Tazobcatam

Interventions

Tazocin 4.5 g iv g 8 hr,PIPTAM 4.5 g iv q 8 hr

Treatment,Treatment

Tazocin,Piptam

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 15 years or above admitted to the hospital and received Piperacillin/Tazobcatam

Exclusion criteria

Exclusion criteria: received piperacillin/tazobactam less than 48 hours

Design outcomes

Primary

Measure	Time frame
To compare the treatment outcome and overall survival day 14, and up to day 28 treatment outcome and overall survival	—

Secondary

Measure	Time frame
To compare the safety during treatment Adverse drug reaction	—

Countries

Thailand

Contacts

Public ContactNAPA SRIYUBON

SIAM

napa.sriyubon@siampharmaceutical.com0814080355

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026